Emmaus Life Sciences Company Description

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.

The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older.

It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers.

Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Emmaus Life Sciences, Inc.

Country	United States
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	33
CEO	Willis Lee

Contact Details

Address: 21250 Hawthorne Boulevard Torrance, California 90503 United States
Phone	310 214 0065
Website	emmausmedical.com

Stock Details

Ticker Symbol	EMMA
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US29137T1016
SIC Code	2834

Key Executives

Name	Position
Willis C. Lee M.S.	Chief Executive Officer and Chairman of the Board
Hiroko Huynh CPA	Chief Accounting Officer
Dr. Charles W. Stark Pharm.D.	Chief Science Officer and Executive Vice President of Clinical Development and Medical Affairs
Dale E. Short J.D.	Legal Consultant and Corporate Secretary
Kurt H. Kruger M.B.A., M.S.	Consultant